Clinical trial • Phase I • Oncology
THE-0504 for Solid tumors
Phase I trial of THE-0504 for Solid tumors. 30 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Solid tumors
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 28-05-2024
- First CTIS Authorization Date
- 16-09-2024
Trial design
Phase I trial across 1 site in Italy.
- Target Sample Size
- 30
Eligibility
Recruits 30 Vulnerable population selected (isVulnerablePopulationSelected = true); no details on consent or assent handling provided..
- Vulnerable Population
- Vulnerable population selected (isVulnerablePopulationSelected = true); no details on consent or assent handling provided.
Recruitment
- Planned Sample Size
- 30
- Recruitment Window Months
- 30
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 30
Italy
- Earliest CTIS Part Ii Submission Date
- 23-08-2024
- Latest Decision Or Authorization Date
- 19-02-2026
- Processing Time Days
- 545
- Number Of Sites
- 1
- Number Of Participants
- 30
Sites
- Site Name
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Department Name
- UOC Fase I
- Contact Person Name
- Gennaro Daniele
- Contact Person Email
- gennaro.daniele@policlinicogemelli.it
Sponsor
Primary sponsor
- Full Name
- Thena Biotech S.r.l.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Italy
Investigational products
- Investigational Product Name
- THE-0504
Related trials
Other published trials that may interest you.
- Oncolytic adenovirus encoding tumor necrosis factor alpha (TNF-alpha) and interleukin-2 (IL-2) for Solid Tumors
- BBO-10203 for Solid Tumors
- AUTOLOGOUS T-CELLS TRANSDUCED WITH THE LENTIVIRAL LV-R11KEA ENCODING T-CELL RECEPTOR TARGETING PATIENT-SPECIFIC TUMOR-ASSOCIATED ANTIGENS for Solid tumors
- Avelumab for Solid Tumors
- BI 1831169 for Solid tumors